Please assess the completion status of the following clinical trial:

Trial Title: Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients whose physicians plan to prescribe low-dose hCG for ovarian stimulation~2. Age 18-46~3. Negative serum hCG prior to start of COH~4. BMI \>18 and \<35~5. Plan for ejaculated sperm use~6. Plan for PGT testing with euploid embryo transfer~Exclusion Criteria:~1. Administration of low-dose hCG during frozen embryo transfer cycle~2. Concomitant Menopur administration during ovarian stimulation or during frozen embryo transfer cycle~3. BMI \<18 or \>35~4. Age \<18 or \>46~5. Presence of hydrosalpinxes that communicate with the endometrial cavity~6. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), and persistent endometrial fluid~7. Uncorrected uterine factor infertility (uterine anomaly, submucosal myomas, uterine septum)~8. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)~9. Use of surgical procedures to obtain sperm~10. Couples undergoing IVF for fertility preservation with no immediate plan for subsequent FET (embryo banking)~11. Personal history of repeated pregnancy loss (two or more unexplained clinical losses defined by presence of fetal heartbeat)~12. Declination of PGT testing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): to remain on current dose of low dose hCG
- Intervention Group (Type: EXPERIMENTAL): increased dose of low dose hCG prescribed

Based on this trial design, predict the completion outcome and termination type (if applicable).